MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Penumbra Operating Income 2011-2026 | PEN
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Penumbra
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 189 M | 9.28 M | 73.6 M | 6.08 M | -7.5 M | -38.9 M | 47.5 M | -852 K | 1.16 M | -1.35 M | 4.18 M | 3.01 M | -1.13 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 189 M | -38.9 M | 21.9 M |
Quarterly Operating Income Penumbra
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48.8 M | 40.8 M | 40.4 M | 35.4 M | -81 M | 12.1 M | 12.6 M | 17.9 M | 8.01 M | - | 5.43 M | -139 K | -4.05 M | - | 8.78 M | 10.3 M | 13.5 M | - | -20.2 M | -17.6 M | 610 K | - | 13 M | 12.8 M | 11.2 M | - | -20.8 M | 9.28 M | 4.04 M | - | 683 K | -1.33 M | -2.05 M | - | -1.36 M | -670 K | 1.84 M | - | 2.18 M | -3.81 M | 3.99 M | - | 311 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 48.8 M | -81 M | 4.73 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M |  USA |
 |
Insulet Corporation
PODD
|
474 M | $ 216.0 | -4.21 % | $ 15.2 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Profound Medical Corp.
PROF
|
-30.3 M | $ 5.82 | 13.01 % | $ 180 M |  Canada |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Quanterix Corporation
QTRX
|
-126 M | $ 3.96 | 3.66 % | $ 169 M | USA |
 |
AVITA Medical
RCEL
|
-42.5 M | $ 3.99 | 3.91 % | $ 111 M |  Australia |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.33 | -1.85 % | $ 21.5 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
IRadimed Corporation
IRMD
|
26.1 M | $ 101.78 | 0.8 % | $ 1.29 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.56 | -0.39 % | $ 7.1 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 37.08 | 1.42 % | $ 1.15 B | USA |
 |
Smith & Nephew plc
SNN
|
593 M | - | - | $ 23.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
-10.3 M | $ 4.22 | 6.57 % | $ 68.9 M | USA |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.66 | -0.16 % | $ 208 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | Canada |
 |
Tactile Systems Technology
TCMD
|
29.3 M | $ 26.96 | 0.37 % | $ 617 M | USA |
 |
TELA Bio
TELA
|
-44.1 M | $ 0.69 | -9.35 % | $ 15.8 M | USA |
 |
Tandem Diabetes Care
TNDM
|
8.29 M | $ 24.26 | -1.02 % | $ 1.65 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.67 | -3.52 % | $ 36.5 M | USA |
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.32 | 7.41 % | $ 3.62 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
InspireMD
NSPR
|
-49.6 M | $ 1.77 | -1.12 % | $ 114 M |  Israel |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 11.39 | -0.78 % | $ 1.54 B | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.7 | -0.1 % | $ 29.3 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-56.7 M | $ 2.29 | -4.58 % | $ 134 M | Israel |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.71 | -5.12 % | $ 138 M |  France |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 16.23 | 2.01 % | $ 381 M | USA |
 |
Outset Medical
OM
|
-66.7 M | $ 3.53 | - | $ 53.7 K | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 51.41 | -1.27 % | $ 1.51 B | USA |
 |
Varex Imaging Corporation
VREX
|
-27.8 M | $ 10.69 | 0.66 % | $ 443 M | USA |